SummitTX Capital’s Edwards Lifesciences EW Stock Holding History

SummitTX Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,374	Closed	-$1.74M	–	775
2025 Q3	$1.74M	Buy	+22,374	New	+$1.75M	0.07%	284

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SummitTX Capital's EW Position: Q4 2025 in Review

SummitTX Capital sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 22,374 shares — an estimated $1.74M sold.

SummitTX Capital first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $1.74M in Q3 2025. 1,315 funds tracked by Wall St. Rank hold EW as of Q4 2025.

SummitTX Capital reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
SummitTX Capital sold 22,374 Edwards Lifesciences shares in Q4 2025, an estimated $1.74M.
SummitTX Capital first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
SummitTX Capital's Edwards Lifesciences position peaked at $1.74M in Q3 2025.
1,315 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.